光正眼科收盘上涨1.94%，最新市净率19.13，总市值21.83亿元

Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of March 31, 2025, the number of shareholders for the company increased to 47,404, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] Group 2 - The company's price-to-earnings (PE) ratio (TTM) is -14.05, and the price-to-book (PB) ratio is 19.13, with a total market capitalization of 2.183 billion yuan [2] - The industry average PE ratio is 38.66, while the industry median is 43.32, indicating that the company is significantly below the industry average in terms of valuation metrics [2] - Comparatively, other companies in the industry have varying PE ratios, with some companies like RunDa Medical showing a PE ratio of -296.69, indicating a wide range of performance and valuation within the sector [2]